Peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform 4 (PGC-1α4)

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform 4 (PGC-1α4) is a specific protein variant derived from the PPARGC1A gene through alternative splicing (Ruas et al., 2012). Unlike the canonical PGC-1α1 isoform, which primarily regulates mitochondrial biogenesis and oxidative metabolism, PGC-1α4 is specifically induced by resistance exercise and functions as a master regulator of skeletal muscle hypertrophy (PubMed: 23217708). It exerts its effects by acting as a transcriptional coactivator that increases the expression of pro-anabolic factors like insulin-like growth factor 1 (IGF-1) while simultaneously suppressing anti-anabolic factors such as myostatin (Cell, 2012). This dual action makes it a critical mediator of muscle mass adaptation to mechanical loading. Because of its ability to promote muscle growth and prevent degradation, PGC-1α4 is a significant therapeutic target for treating muscle-wasting conditions, including sarcopenia, cancer-induced cachexia, and age-related frailty (NIH: PMC3523077). While no FDA-approved drugs currently target PGC-1α4 specifically, it remains a focus of drug discovery efforts aimed at developing exercise mimetics that can preserve muscle function in sedentary or diseased populations. Selective activation of this isoform is preferred over global PGC-1α activation to avoid interfering with oxidative metabolism or causing off-target metabolic shifts.

Other names

PGC-1alpha4PPARGC1A isoform 4PGC-1a4truncated PGC-1alpha

PGC-1α4 acts as a transcriptional coactivator that induces the expression of insulin-like growth factor 1 (IGF-1) and suppresses the expression of myostatin, thereby promoting skeletal muscle hypertrophy (Ruas et al., 2012).